Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136487 · ClinicalTrials.gov registry record · Phase 2
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00136487 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 85 participants.
The verdict
NCT00136487, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
The purpose of this study is to learn the effects (both good and bad) that celecoxib has on prostate cancer and patients with prostate cancer. This study is looking at what effects celecoxib has on prostate specific antigen (PSA) level. PSA is a marker specific to prostate cancer. An increase or decrease in this level in the blood can indicate if a patient's prostate cancer is getting worse or better.
Interventions
- DRUG Celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136487
The ClinicalTrials.gov registry entry for NCT00136487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Celecoxib is the first listed.
NCT00136487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00136487 about?
NCT00136487 is a clinical study titled "Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer". The purpose of this study is to learn the effects (both good and bad) that celecoxib has on prostate cancer and patients with prostate cancer. This study is looking at what effects celecoxib has on prostate specific antigen (PSA) level. PSA is a marker specific to prostate cancer. An increase or dec...
What is the current status of trial NCT00136487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2002-10. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00136487?
The interventions under investigation include: Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00136487?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.